Bora — Proxy Solicitation & Information Statement 2026

May 21, 2026

Stock Code: 6472

bora

Bora Pharmaceuticals

Bora Pharmaceuticals CO., LTD.

Notice of 2026 Annual General Shareholders' Meeting (Summary Translation)

I. The 2026 Annual General Shareholders' Meeting (the "Meeting") of Bora Pharmaceuticals CO., LTD. (the "Company") will be held at 9:00 a.m. on Tuesday, June 9, 2026 at No.2, Gongye Rd., Guantian Dist., Tainan City 720, Taiwan (R.O.C.)

II. Proposed Agenda:

(1) Report Items:

1. 2025 Business Operation Report.
2. 2025 Audit Committee’s Audit Report.
3. Report on 2025 Employees' and Directors' Compensation.
4. Report on 2025 Surplus Distribution in the form of Cash Dividend.
5. Report on the Execution of Treasury Stock.
6. Report on the Issuance of the Company’s 4th and 5th Domestic Unsecured Convertible Corporate Bonds and the 1st Foreign Unsecured Convertible Corporate Bonds.

(2) Proposal Items:

1. Adoption of the 2025 Business Operation Report and Financial Statements.
2. Adoption of the 2025 Earnings Distribution.

(3) Election and Discussion Items:

1. Election for Directors.
2. To Discharge Board of Directors’ Non-Compete Clause.
3. Amendment on the Procedure for Acquiring and Disposing Asset.
4. Amendment on the Procedure for Shareholders Meetings

---

(4) Extraordinary Motions.

III. The proposed distribution of 2025 profits adopted by the Board of Directors is that each shareholder will be entitled to receive a cash dividends of NT$10.0 per share. The ex-dividend record date for cash dividend distribution to be set by the chairman.

IV. Should there be items related to article 172 of the Company Act or article 26-1 of the Securities and Exchange Act on the agenda of the shareholders' meeting, their major contents, in addition to inclusion in the notice for the meeting, be posted on the Market Observation Post System (https://mops.twse.com.tw).

V. In accordance with the provisions of article 165 of the Company Act, share transfer registration is temporarily ceased from April 11, 2026 to June 9, 2026.

VI. The Company will compile and post a general list of information on calls for proxies, if any, by May 8, 2026, on the Securities & Futures Institute website (http://free.sfi.org.tw). Investors may conduct search for the information by logging on the above site. The Stock Transfer Agency Department of Taishin Securities Co., Ltd. will certify the tally of proxies.

VII. The shareholder meeting will elect 7 directors, including 4 independent directors. The nomination for director candidates are Sheng Pao-Shi, Bao Lei Co., Ltd’s representative Chen Kuan-Pai, and Wang Chin-Chu. The nomination for independent director candidates are Lee Yi-Chin, Lai Ming-Jung, and Lin Hsin-I, Yao Leroy. For candidates’ educational background and major experience, please refer to Market Observation Post System (https://mops.twse.com.tw).

VIII. To attend the Annual Shareholders’ Meeting in person, please fill in the Form of Attendance Notice for registration on the day of the Meeting. To attend by proxy, please refer to the guidance of Proxy, fill in and return the Form of Proxy Attendance. The Form of Proxy Attendance shall be delivered to the Stock Transfer Agency Department of Taishin Securities Co., Ltd. FIVE (5) days prior to the day of Annual Shareholders’ Meeting.

IX. Voting right for the shareholders’ meeting can be exercised via electronic form during

2

---

the period from May 9, 2026 to June 6, 2026. Please access Shareholder e-voting at the website of Taiwan Depository and Clearing Corporation.
(https://www.stockservices.com.tw)

X. Please bring your identification card for verification if you are attending the annual meeting in person.

XI. Please acknowledge for the above information.

Board of Directors
Bora Pharmaceuticals CO., LTD.

3